Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Griffith

Showing results (81-90 of 511) with videos related to

Pageof 52
Sort By:
Immunological Reviews|September 16, 2006
A vision of cell death: Fas ligand and immune privilege 10 years laterThomas A Ferguson, Thomas S Griffith
Lancet (London, England)|February 27, 1971
Cephalexin and oral cephalosporinR S Griffith, W I Shedden
European Journal of Pharmacology|October 20, 2009
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapiesPeter A Holoch, Thomas S Griffith
Current Psychiatric Therapies|January 1, 1978
Race and psychotherapy: changing perspectivesM S Griffith, E E Jones
Cancers|July 30, 2016
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasKatherine A Murphy, Thomas S Griffith
Journal of Clinical Immunology|January 1, 1997
Cell death and the immune response: a lesson from the privilegedT A Ferguson, T S Griffith
Immunology Today|May 1, 1997
The role of FasL-induced apoptosis in immune privilegeT S Griffith, T A Ferguson
Immunological Reviews|April 1, 1997
A vision of cell death: insights into immune privilegeT A Ferguson, T S Griffith
Journal of the American Society for Mass Spectrometry|November 15, 2013
A simple method for estimating effective ion source residence timeK S Griffith, G I Gellene
Cancer Research|December 20, 2007
Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapyRebecca L VanOosten, Thomas S Griffith
Pageof 52

Showing results (81-90 of 511) with videos related to

Sort By:
Pageof 52
Immunological Reviews|September 16, 2006
A vision of cell death: Fas ligand and immune privilege 10 years laterThomas A Ferguson, Thomas S Griffith
Lancet (London, England)|February 27, 1971
Cephalexin and oral cephalosporinR S Griffith, W I Shedden
European Journal of Pharmacology|October 20, 2009
TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapiesPeter A Holoch, Thomas S Griffith
Current Psychiatric Therapies|January 1, 1978
Race and psychotherapy: changing perspectivesM S Griffith, E E Jones
Cancers|July 30, 2016
CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant GliomasKatherine A Murphy, Thomas S Griffith
Journal of Clinical Immunology|January 1, 1997
Cell death and the immune response: a lesson from the privilegedT A Ferguson, T S Griffith
Immunology Today|May 1, 1997
The role of FasL-induced apoptosis in immune privilegeT S Griffith, T A Ferguson
Immunological Reviews|April 1, 1997
A vision of cell death: insights into immune privilegeT A Ferguson, T S Griffith
Journal of the American Society for Mass Spectrometry|November 15, 2013
A simple method for estimating effective ion source residence timeK S Griffith, G I Gellene
Cancer Research|December 20, 2007
Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapyRebecca L VanOosten, Thomas S Griffith
Pageof 52